July 8, 2021 07:10 AM EDTUpdated July 9, 07:51 AM
FDA+

In pur­suit of a block­buster, Am­gen and As­traZeneca score pri­or­i­ty re­view for asth­ma drug teze­pelum­ab

Amber Tong

Am­gen and As­traZeneca are one big step clos­er to re­al­iz­ing their block­buster dreams for teze­pelum­ab af­ter the FDA grant­ed a pri­or­i­ty re­view for the asth­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

A service from the Financial Times